TP53 and lung adenocarcinoma: To investigate the impact of the KRAS and TP53 mutations on the benefit of ICI in an independent and broader patient population, we analysed a large cohort of patients with lung adenocarcinoma from the Thoraxklinik Heidelberg (HD-ICI) and two external cohorts including patients treated with ICI monotherapy and combination therapy of ICI with platinum-based chemotherapy.